Physician profile
Thomas Terenzi
NPI 1922001940
$1,879.55
in general payments reported to CMS, 2019-2025
15 companies · $460 in 2025
The $460 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $248 · 2021: $14.31 · 2022: $56.43 · 2023: $240 · 2024: $424 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,029 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,029.48 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $610.32 | 2019-2025 | Tavneos, Enbrel, Uplizna |
| Abbvie INC. | $455.96 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $155.89 | 2023-2025 | Tremfya |
| Aurinia Pharma U.S., INC. | $129.71 | 2023-2024 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $111.33 | 2024-2025 | Orencia |
| Lilly USA, LLC | $111.27 | 2019-2025 | Zepbound |
| Ucb, INC. | $64.26 | 2024-2025 | Bimzelx |
| Genzyme Corporation | $61.51 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $32.68 | 2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $30.68 | 2024 | Saphnelo |
| Kiniksa Pharmaceuticals International, Plc | $30.51 | 2024 | Arcalyst |
| Organon LLC | $25.81 | 2023-2025 | Hadlima |
| Novartis Pharmaceuticals Corporation | $25.26 | 2025 | |
| Glaxosmithkline, LLC. | $20.05 | 2024 | Benlysta |
| Pfizer INC. | $14.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Terenzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.